Is Promega Corporation profitable?

Promega is privately held and does not disclose profit figures. It states it invested 13.8% of 2024 revenue into R and D, per its own August 2025 press release, but no audited profit or revenue figures are publicly available since it is not a reporting company.

Who owns Promega Corporation?

Promega is independently and privately held with no parent company, according to its own company facts sheet. Founder William A. Linton, who started the company in 1978 as Biotec before renaming it Promega, remains listed as Chairman and CEO on Promega's own materials.

Could AI replace Promega's products?

No. Promega makes physical reagents, enzymes and forensic DNA kits like PowerPlex, which require wet-lab chemistry and accredited manufacturing that AI cannot substitute. Adjacent informatics tasks like primer design are being AI-augmented industry-wide, but Promega's core catalog is untouched as of 2026.

Who is Promega's biggest competitor?

Promega's forensic DNA kit PowerPlex competes directly with Qiagen's Investigator and Thermo Fisher's GlobalFiler systems, per a Qiagen-published kit comparison. Thermo Fisher, Qiagen, Bio-Rad, Roche and Merck KGaA/MilliporeSigma are named as Promega's closest peers in molecular biology reagents markets.

Is it safe to take a job at Promega Corporation?

Promega had 1,916 employees worldwide as of December 2025, down 1.5% from 1,944 in 2024, per Revelio Labs workforce data published June 2026. The company was also named a BioSpace 2026 Best Places to Work winner in November 2025.

Has Promega won any patent lawsuits recently?

Yes. Promega resolved a patent infringement lawsuit against Aobious Inc. in August 2025 over NanoLuc substrate (furimazine) patents, reinforcing its bioluminescence IP moat, according to a Promega press release dated August 4, 2025.

Biotech tools companies · United States

Promega Corporation

promega.com ↗

Private US maker of molecular biology reagents, enzymes, and forensic DNA kits.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: NanoPrism luciferase moves from early access waitlist toward full commercial launch

The call

Promega's patented enzyme chemistry and entrenched forensic lab workflows keep bigger rivals at bay, while AI has no role in its core wet lab business.

Promega sells specialty chemicals and DNA kits used by research labs and crime labs around the world. It is hard to replace because it owns important patents (especially for a glowing protein called NanoLuc), crime labs are locked into using its forensic kits as part of their official procedures, and Promega makes most of its own products in-house rather than outsourcing. Bigger companies like Thermo Fisher and Roche cannot simply buy or outspeed their way in because the patents block them and labs cannot easily switch without re-certifying their work. AI cannot help rivals here because the real work is mixing chemicals in test tubes, not processing information. The biggest risk is that the founder, Bill Linton, has run the company since 1978, and when he eventually steps back, a new owner might run things differently or sell the company to someone else.

Why

AI pressure: None apparent. AI can't synthesize enzymes or run wet lab assays; it only speeds adjacent tasks like primer design, not the core product. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific, Qiagen, and Merck KGaA's MilliporeSigma. These giants already sell competing reagent and luciferase lines, but Promega's patents and lab workflow lock-in block easy swaps. Could a giant copy it? No, they are blocked.

What protects it. Patent-protected NanoLuc and furimazine chemistry, forensic lab workflow lock-in, and 85%+ in-house manufacturing keep customers from switching.

What would change this call

Vazyme or Yeasen announces a validated forensic or clinical diagnostic kit within 12 months. Would show Chinese entrants moving beyond commodity reagents into Promega's protected niches.
News confirms whether Bill Linton remains Promega CEO/Chairman or has been succeeded. Clarifies founder-control status, a key part of Promega's independence-based moat.
Promega files or wins another patent-infringement suit over NanoLuc or furimazine within a year. Shows whether IP enforcement is holding rivals back from the core reporter-technology moat.

Key numbers

13.8% of 2024 revenue spent on R&D (2024)
Founded 1978, Bill Linton still Chairman/CEO (2026-05-05)
85%+ of 3,500+ products made in-house (n.d.)

Named risks

Founder succession risk with Bill Linton having led the company since 1978, with no confirmed succession plan disclosed. Severity: medium
Low-cost Chinese reagent makers eroding margins on commodity catalog lines outside patent-protected niches. Severity: medium
Continued reliance on active IP litigation (e.g., Aobious case) to defend NanoLuc and furimazine substrate exclusivity. Severity: medium
Conflicting third-party leadership and revenue data (e.g., disputed CEO listing) reduces public visibility into company health. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	GlobalFiler forensic kit competes directly with Promega's PowerPlex, per Qiagen kit comparison, n.d.
Qiagen	contesting	Investigator forensic kits compete with PowerPlex and PowerQuant in accredited forensic labs, n.d.
Merck KGaA / MilliporeSigma	contesting	Signed co-development partnership with Promega on 3D cell tech in October 2025, while remaining a broader market peer
Vazyme and Yeasen (Chinese reagent makers)	gaining on	Low-cost Chinese manufacturers cited as eroding commodity reagent margins as of April 2026 market report

Questions people ask

Is Promega Corporation profitable?: Promega is privately held and does not disclose profit figures. It states it invested 13.8% of 2024 revenue into R and D, per its own August 2025 press release, but no audited profit or revenue figures are publicly available since it is not a reporting company.
Who owns Promega Corporation?: Promega is independently and privately held with no parent company, according to its own company facts sheet. Founder William A. Linton, who started the company in 1978 as Biotec before renaming it Promega, remains listed as Chairman and CEO on Promega's own materials.
Could AI replace Promega's products?: No. Promega makes physical reagents, enzymes and forensic DNA kits like PowerPlex, which require wet-lab chemistry and accredited manufacturing that AI cannot substitute. Adjacent informatics tasks like primer design are being AI-augmented industry-wide, but Promega's core catalog is untouched as of 2026.
Who is Promega's biggest competitor?: Promega's forensic DNA kit PowerPlex competes directly with Qiagen's Investigator and Thermo Fisher's GlobalFiler systems, per a Qiagen-published kit comparison. Thermo Fisher, Qiagen, Bio-Rad, Roche and Merck KGaA/MilliporeSigma are named as Promega's closest peers in molecular biology reagents markets.
Is it safe to take a job at Promega Corporation?: Promega had 1,916 employees worldwide as of December 2025, down 1.5% from 1,944 in 2024, per Revelio Labs workforce data published June 2026. The company was also named a BioSpace 2026 Best Places to Work winner in November 2025.
Has Promega won any patent lawsuits recently?: Yes. Promega resolved a patent infringement lawsuit against Aobious Inc. in August 2025 over NanoLuc substrate (furimazine) patents, reinforcing its bioluminescence IP moat, according to a Promega press release dated August 4, 2025.

Timeline

2026-04-28Promega authorizes UBC RNA and Formulation Core to distribute NanoLuc-encoding mRNA constructs
2026-04-15Promega reveals red-shifted NanoPrism luciferase technology at AACR Annual Meeting 2026
2025-11-04Promega named a BioSpace 2026 Best Places to Work winner
2025-10-27MilliporeSigma (Merck KGaA) signs co-development partnership with Promega on 3D cell technologies
2025-08-04Promega and Aobious resolve NanoLuc substrate patent infringement lawsuit
2025-04-08Promega Corporation files patent suit against Aobious Inc. in Delaware district court
1978Company founded by Bill Linton as Biotec, later renamed Promega

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE